Storia in 2 fonti

This Glaucoma Therapy Company Is Keeping An Eye On Profits

Glaukos stock is in the buy zone of a base. The glaucoma treatment developer raised its revenue forecast in its latest earnings report.

Raccontata da

morningstar.com

investors.com

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

investors.comStai leggendo1 mese fa

This Glaucoma Therapy Company Is Keeping An Eye On Profits

Glaukos stock is in the buy zone of a base. The glaucoma treatment developer raised its revenue forecast in its latest earnings report.

originale

morningstar.com1 mese fa

Glaukos to Release Second Quarter 2026 Financial Results after Market Close on July 29

Glaukos to Release Second Quarter 2026 Financial Results after Market Close on July 29Conference Call and Webcast Scheduled for 1:30 p.m. PTGlaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical…

Leggi questa versione → originale

Timeline cronologica

mercoledì 8 luglio 2026·morningstar.com
Glaukos to Release Second Quarter 2026 Financial Results after Market Close on July 29
Glaukos to Release Second Quarter 2026 Financial Results after Market Close on July 29Conference Call and Webcast Scheduled for 1:30 p.m. PTGlaukos Corporation (NYSE: GKOS), an…
mercoledì 8 luglio 2026·investors.com
This Glaucoma Therapy Company Is Keeping An Eye On Profits
Glaukos stock is in the buy zone of a base. The glaucoma treatment developer raised its revenue forecast in its latest earnings report.